Business Wire

Antler Raises Over $300m and Expands Investment Focus to Invest Up to Series C

13.10.2021 16:05:00 EEST | Business Wire | Press release

Share

Global venture capital firm Antler has announced that it has closed over $300m to date, allowing it an opportunity to provide continued support to its companies in subsequent funding rounds. Investors in the funds include Schroders, Vækstfonden, and Phoenix Group.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211013005689/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Antler's Demo Day in London (Photo: Business Wire)

Antler is on a mission to fundamentally improve the world by enabling and investing in the world's most exceptional people. The primary focus of the firm will remain investing at the pre-seed stage, with the firm now also having the ability to offer its portfolio companies follow-on capital as they grow and scale, up to Series C.

Magnus Grimeland, CEO and Founder of Antler, said “We continue to provide support for our founders from the earliest stages, and are thrilled to be able to continue investing in them as they grow. We look forward to backing even more entrepreneurs that are redefining industries in the future.”

Antler is continually developing and expanding its senior team, and its global presence. To this end, Antler has recruited new partners Naman Budhdeo, Erik Jonsson, Jiho Kang, and Subir Lohani to lead its new Canada, Vietnam, Korea, and Indonesia teams respectively.

Teddy Himler from SoftBank also joins as a Partner of the later-stage investment team.

Antler has invested in over 350 companies globally across over 30 different industries since 2018. Of these companies, 40% have at least one female co-founder, with 70 nationalities represented.

Antler continues to invest in its portfolio companies as they scale. The firm has a global network of over 600 expert advisors, and an online platform of resources, tools and supports its portfolio companies with introductions to global investors, hands-on assistance with new market entry, and access to a global network of expert advisors.

In providing continued support and investment, Antler confirms its position as a long-term partner for exceptional entrepreneurs -- from the outset of their journey, to the later stages as they scale.

Antler also intends to now invest in a number of companies from outside of its portfolio at seed and Series A stages. Antler has put together a team to oversee on-going investments, led by Antler partners: Martell Hardenberg, Co-Founder of Lazada; Teddy Himler, formerly of SoftBank; Stefan Jung, previously Managing Partner at Venturra Capital; and Navi Singh, a Researcher at MIT's Department of Mechanical Engineering.

This on-going evolution is built on what we believe to be a strong structural advantage in deal flow sourcing from regionally focused early-stage investments across 15 countries in 5 continents, including: Australia (Melbourne and Sydney), Canada (Toronto), Denmark (Copenhagen), Germany (Berlin), India (Bangalore), Indonesia (Jakarta), Kenya (Nairobi), Norway (Oslo), Sweden (Stockholm), Singapore, South Korea (Seoul), The Netherlands (Amsterdam), The UK (London), US (Austin and New York), and Vietnam (Ho Chi Minh).

Lieven Debruyne, Global Head of Distribution at Schroders said, “As a longstanding partner and investor in Antler, we are delighted to continue our investment in Antler. It is a unique opportunity to gain exposure to a global growth portfolio of innovative technology companies, and to ensure a steady stream of capital is being invested in companies that will define how we all live and work in the future”

Lars Nordal Jensen, Senior Director at Vækstfonden said, “We are thrilled to continue our commitment to Antler. We have previously invested in Antler, and have been delighted with the firm’s overwhelmingly positive contribution to the technology ecosystem since their market entry. In Vaekstfonden we want to help drive innovation and new technology, and therefore we are very pleased to see Antler continue its commitment to supporting innovative founders throughout their journey”

THIS PRESS RELEASE IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. NO OFFERING OF INTERESTS OF THE FUNDS REFERRED TO ABOVE HAS BEEN OR WILL BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER ANY OTHER U.S. FEDERAL AND STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN THE UNITED STATES OR TO U.S. INVESTORS, UNLESS THEY ARE REGISTERED, OR EXEMPT FROM, OR NOT SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT.

-ENDS-

About Antler

Antler is a global early-stage venture capital firm that invests in the defining technology companies of tomorrow. The firm has offices globally across most major entrepreneurial hubs, including in London, Berlin, Stockholm, New York, Singapore and Sydney.

Founded in Singapore in 2017, Antler is on a mission to fundamentally improve the world by enabling and investing in the world's most exceptional people, by building complementary co-founder teams, supporting the teams with deep business model validation and providing a global platform for scaling. To date, Antler has invested in over 350 companies globally across 30 different industries. Of these companies, 40% have at least one female co-founder, and the founders represent 70 nationalities. Antler’s current portfolio of startups includes: HomeBase, Reebelo, Qashier, Volopay, Pathzero, Marco Financial , Xanpool, PowerX, and Xailient.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ben Goldsmith
ben@goldsmithcomms.com
+44(0)7788295321

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye